| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3977874 | Brachytherapy | 2012 | 13 Pages |
Abstract
The clinical outcomes for HDR are excellent, with high rates of biochemical control, even for high-risk disease, with low morbidity. HDR monotherapy, both for primary treatment and salvage, are promising treatment modalities.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Yoshiya Yamada, Leland Rogers, D. Jeffrey Demanes, Gerard Morton, Bradley R. Prestidge, Jean Pouliot, Gil'ad N. Cohen, Marco Zaider, Mihai Ghilezan, I-Chow Hsu,